Therapy Registry for Chinese Ischemic Stroke Within 6 h Onset "TRECIS"

Not yet recruiting

Phase N/A Results N/A

Summary of Purpose

Stroke is one of the leading causes of death and disability in China. Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) improves the outcome for ischemic stroke patients who can be treated within 4.5 hours of symptom onset. In China, in addition to rt-PA, intravenous urokinase within 6 h has also been recommended by the 2010 Chinese Guidelines for the Diagnosis and Treatment of...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 11 August 2016.

1 Aug 2016 29 Jul 2016 1 Feb 2019 1 Aug 2019 1 Aug 2016 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Observation: Cohort
  • Perspective: Prospective
  • Sampling: Non-Probability Sample

Contacts

See All